Loading data
DNANYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 170.16 m USD | 227.04 m USD | 251.46 m USD | 477.71 m USD | 313.84 m USD |
| Research and development expense | 243.77 m USD | 424.06 m USD | 580.62 m USD | 1.05 bn USD | 1.15 bn USD |
| Operating profit | -315.28 m USD | -559.76 m USD | -864.41 m USD | -2.21 bn USD | -1.83 bn USD |
| Interest expense | — | — | 93 k USD | 106 k USD | 2.37 m USD |
| Profit before tax | -313.6 m USD | -547.51 m USD | -892.94 m USD | -2.12 bn USD | -1.84 bn USD |
| Income tax expense | -837 k USD | -479 k USD | -71 k USD | -15.03 m USD | -1.48 m USD |
| Net income (reported basis) | -313 k USD | -547 k USD | -893 k USD | -2.11 m USD | -1.83 m USD |
| Basic earnings per share | -5.64 USD/share | -10.54 USD/share | -18.37 USD/share | -50.15 USD/share | -1.35 USD/share |
| Diluted earnings per share | -5.64 USD/share | -10.54 USD/share | -18.37 USD/share | -50.2 USD/share | -1.39 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.